January 17, 2018 / 12:51 PM / 6 months ago

BRIEF-Onconova Says Moving Forward With Pivotal Late-Stage Trial

Jan 17 (Reuters) - Onconova Therapeutics Inc:

* ONCONOVA MOVING FORWARD WITH PHASE 3 INSPIRE PIVOTAL TRIAL WITH INCREASED SAMPLE SIZE FOLLOWING PROMISING INTERIM ANALYSIS

* ONCONOVA - DMC RECOMMENDS CONTINUATION OF INSPIRE TRIAL WITH TRIAL EXPANSION PER ADAPTIVE DESIGN BASED ON INTERIM ANALYSIS RESULTS FOR OS

* ONCONOVA - TRIAL EXECUTIVE COMMITTEE UNANIMOUSLY AGREED TO CONTINUE INTENT TO TREAT STUDY POPULATION, INCREASE CLINICAL TRIAL ENROLLMENT

* ONCONOVA - EXPANDED INSPIRE STUDY WILL INCREASE ENROLLMENT BY ADDING 135 PATIENTS TO ORIGINAL TARGET, TO REACH TOTAL ENROLLMENT OF 360 PATIENTS Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below